LFB USA is led by a team of business experts and scientists with a successful track record of developing and commercializing important and highly innovative healthcare technologies and life-changing therapeutics.
Dr. Gavin has served as the company’s President since April 2014 and previously held various positions of increasing responsibility within the Company since 1994. Prior to becoming President, he was Senior Vice President of Operations and responsible for the company’s production programs and transgenic animal development as well as many of the Operational components within the company including Farm Operations, Dairy Operations, Veterinary Services, Facilities, Occupational Health and Safety, Security and Logistics. Dr. Gavin has been with the company for 20+ years and working in this field and with this platform of production for 25+ years. Dr. Gavin is well published, presents internationally, and is also named on numerous international patents. He was instrumental in the development of the production facility in central Massachusetts and responsible for overseeing the site through to the first ever Regulatory approval and licensure for the rPRO Technology™ by the EMA, FDA-CBER and FDA-CVM. He holds a Bachelors degree in Animal Science with honors from the University of Massachusetts and a Doctorate in Veterinary Medicine with honors from Tufts University.
Dr. Evans joined the company in 2006. He leads a multi-disciplinary team focused in the CMC areas of formulation, analytical and process development, technology transfer, scale-up, QC and manufacturing for LFB-USA products, partners and clients. Prior to joining the company in 2006, he worked/consulted for various pharmaceutical companies (Interferon Sciences, E.R. Squibb & Sons, Bristol-Myers-Squibb, ImmuLogic, Creative Biomolecules, Stryker, Syntonix and Critical Therapeutics) and has developed various, parenteral, oral, implantable and pulmonary products. He has over 32 years of scientific and management experience in the pharmaceutical development of small molecule, peptide and protein products. Dr. Evans is a Registered Pharmacist and received both his B.S. in Pharmacy and his Ph.D. in Pharmaceutical Sciences/Industrial Pharmacy from Rutgers University.
Dr. Lawrence joined the company in 2015. He has twenty years of experience in the pharma/biotech and diagnostics industry in Clinical Development, Translational Medicine, and Medical Affairs at Eli Lilly, BD, Osiris Therapeutics, and Ipsen, where he played key roles in the development of small molecules, biologics, cellular therapy products, and innovative diagnostics. Before joining industry, he held academic research and clinical roles with increasing responsibility at the NIH, Medical College of Virginia, and Case Western Reserve University where he was Associate Professor of Pathology and Director of Hematology and Hematopathology. He obtained his BS and MD degrees from Northwestern University, and trained in anatomic and clinical pathology, hematopathology, and clinical hematology at Northwestern University, Medical College of Virginia, and NIH; he is board certified in anatomic and clinical pathology and hematology. His research interests have been predominantly in hemostasis and thrombosis and platelet physiology, oncology, companion diagnostics, and early drug development, and he is widely published in both basic laboratory and clinical research.
Harry M. Meade joined in 1994, and is a founding member of the company. Dr. Meade directs all transgenic molecular biology research and development efforts conducted within the company, including the evaluation of technologies having potential to increase the efficiencies of transgenic protein expression.
Dr. Meade has over 25 years of research experience, the last ten years' pertaining to transgenic research and the development of protein expression systems. He has held scientific positions with Genzyme Corporation, Biogen and Merck. Dr. Meade also is a co-inventor on the first issued patent relating to the production of therapeutic proteins in the milk of animals.
Dr. Meade received his Ph.D. in Biology from the Massachusetts Institute of Technology and completed his post-doctoral studies at Harvard University. He holds Bachelor's degrees in Chemistry and Electrical Engineering from Union College.
Michael Megna joined the company as controller in July 2012 and now holds the position of Vice President of Finance and Accounting. He brings over 20 years of experience in corporate finance and accounting. From April 2011 to June 2012, Mr. Megna worked for Harvest Power, Inc. as controller. Prior to that he held the position of corporate controller and chief accounting officer at BioSphere Medical, Inc. until it was acquired by Merit Medical Systems in 2010. He has also held various positions at PricewaterhouseCoopers LLP and Helix Technology Corporation (now part of Brooks Automation). Mr. Megna holds a Bachelor of Business Administration from Siena College, and was licensed as a certified public accountant.
Mr. Neumann joined the company in 2015. He has over three decades of management experience in Quality and Manufacturing Operations including key leadership roles at Genentech, Chiron and Ipsen. Prior to joining LFB-USA, Mr. Neumann was Sr. Director of Quality at the Sarepta Therapeutics Cambridge/Andover, MA and Corvallis, OR sites with management responsibility for Quality Assurance, Quality Control, Analytical Development, Validation and Compliance. Prior to Sarepta Therapeutics, Mr. Neumann served in various escalating roles of responsibility starting at Genentech (Manufacturing Manager), Chiron (QA Director) and Ipsen (VP of Quality). Mr. Neumann holds a Bachelor of Arts degree in Biology.
Richard Scotland joined in 2002 and holds the position of Senior Vice President, Regulatory Affairs. Mr. Scotland is responsible for directing worldwide regulatory activities pertaining to the development of our therapeutic proteins.
Mr. Scotland has over 20 years of regulatory affairs experience with various biotechnology and pharmaceutical companies including Serono Laboratories, Genzyme Corporation and Astra Pharmaceuticals.
Richard Scotland holds a Bachelor's degree in Biology from St. Joseph's College in North Windham, Maine.
Mr. Blash has served as the General Manager of the Company’s Charlton Production Site since early 2017 and had previously held various positions of increasing responsibility within the organization since starting with the company in 1997. Prior to becoming General Manager, he was Assistant General Manager of Operations and responsible for the company’s production programs covering multiple species of transgenic animals. He serves on the company’s IACUC committee as a voting member and is responsible the Operational components within the company including Farm Operations, Dairy Operations, Veterinary Services, Facilities, Occupational Health and Safety, Security and Logistics. Mr. Blash holds a Bachelor’s degree in Biology from St. Joseph's College in North Windham, Maine and a Master of Science Degree in Biotechnology from Worcester State University.